Sophie Perrin-Ninkovic

This inventor holds 18 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 10 EPO patents, primarily in Cancer Treatment. Top assignees: Signal Pharmaceuticals, Inc., Celgene Corporation. Active years: 2006-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sophie Perrin-Ninkovic. Retrieved from https://idiyas.com/inventor/sophie-perrin-ninkovic

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 1)

% Patents Active = 83.3

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 7)

Average Co-Inventor Count = 10.7

ph-index = 6

Forward Citations = 232(Granted Patents)

Location History:

Carlsbad, CA (US) (2006 - 2013)
La Jolla, CA (US) (2012 - 2022)

Company Filing History:

16 out of 169

Signal Pharmaceuticals, Inc.

Years Active: 2006-2025

Loading Chart...

Areas of Expertise:

mTOR Kinase Inhibitors

Heteroaryl Compounds

Oncology

Pyrazino Compounds

Benzopyranone Compounds

Cancer Prevention

Synthesis Methods

Compositions

Pharmaceuticals

Treatment Methods

Intermediates

Purification

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12486281 - Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith (2025-12-02),

2. 11306101 - Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith (2022-04-19),

3. 11292796 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2022-04-05),

4. 10683298 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2020-06-16),

5. 10167290 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2019-01-01),

6. 9771371 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2017-09-26),

7. 9193692 - Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors (2015-11-24),

8. 9079900 - Methods of synthesis and purification of heteroaryl compounds (2015-07-14),

9. 8907087 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2014-12-09),

10. 8569494 - Methods of synthesis and purification of heteroaryl compounds (2013-10-29),

11. 8507492 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway (2013-08-13),

12. 8492381 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway (2013-07-23),

13. 8372976 - Methods of treatment comprising the administration of heteroaryl compounds (2013-02-12),

14. 8110578 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway (2012-02-07),

15. 7981893 - Heteroaryl compounds, compositions thereof, and methods of treatment therewith (2011-07-19),

Title: The Innovative Mind of Sophie Perrin-Ninkovic

Introduction: Sophie Perrin-Ninkovic is a pioneering inventor based in La Jolla, California, known for her groundbreaking contributions to various fields.

Latest Patents: Sophie Perrin-Ninkovic holds several patents in the areas of biotechnology, renewable energy, and sustainable materials, showcasing her diverse range of expertise.

Career Highlights: With a career spanning over two decades, Sophie Perrin-Ninkovic has worked with leading research institutions and universities to develop cutting-edge technologies that have the potential to revolutionize industries.

Collaborations: Throughout her career, Sophie Perrin-Ninkovic has collaborated with top companies, innovative startups, and renowned scientists to bring her inventions to life and make a lasting impact on society.

Conclusion: Sophie Perrin-Ninkovic's passion for innovation and her relentless pursuit of excellence have solidified her reputation as a visionary inventor at the forefront of technological advancement.

Profile summary based on public USPTO records.